A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA

Sharon E. Frey, Kathleen R. Lottenbach, Heather Hill, Tamara P. Blevins, Yinyi Yu, Ying Zhang, Karen E. Brenneman, Sandra M. Kelly-Aehle, Caitlin McDonald, Angela Jansen, Roy Curtiss

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Live, attenuated, orally-administered Salmonella strains are excellent vectors for vaccine antigens and are attractive as vaccines based on previous use of S. Typhimurium in animals. A Phase I dose escalation trial was conducted to evaluate the safety and immunogenicity of three newly constructed recombinant attenuated Salmonella enterica serovar Typhi vaccine (RASV) vectors synthesizing Streptococcus pneumoniae surface protein A (PspA). Methods: The 3 S. Typhi strains used as vectors to deliver PspA were S. Typhi ISP1820; S. Typhi Ty2 RpoS-; and S. Typhi Ty2 RpoS+. Sixty healthy adults (median age 25.2 years) were enrolled into 4 Arms (total 15 subjects per Arm); within each Arm, subjects were randomized 1:1:1 into 3 Groups of 5. All subjects in the same Group received the same vaccine vector, and all subjects in the same Arm received the same titer of vaccine (107, 108, 109 or 1010CFU). Adverse events, safety, shedding, and IgG and IgA titers against Salmonella outer membrane proteins (OMPs), lipopolysaccharide (LPS) and PspA were evaluated. Results: In the highest dose group, no subject experienced severe reactions or serious adverse events. Most adverse events were mild; one subject had a positive blood culture. No subject shed vaccine in stool. No statistically significant differences for post vaccination ELISA or ELISPOT results between Groups were detected. However, a limited number of ≥4 fold increases from baseline for IgA anti-OMPs, IgA and IgG anti-LPS, and IgA anti-PspA occurred for a few individuals as measured by ELISA, and IgA anti-OMPs as measured by ELISPOT assay. Conclusions: All three S. Typhi vectored pneumococcal vaccines were safe and well-tolerated. Immunogenicity was limited possibly due to pre-existing high antibody titers prior to vaccination. Increases in IgA were most often observed.

Original languageEnglish (US)
Pages (from-to)4874-4880
Number of pages7
JournalVaccine
Volume31
Issue number42
DOIs
StatePublished - Oct 1 2013

Fingerprint

Salmonella Vaccines
vector vaccines
Salmonella Typhi
Attenuated Vaccines
Salmonella typhi
Streptococcus pneumoniae
surface proteins
Staphylococcal Protein A
Surface Antigens
pneumonia
Pneumonia
Membrane Proteins
antigens
Vaccines
outer membrane proteins
dosage
vaccines
Enzyme-Linked Immunospot Assay
lipopolysaccharides
Salmonella

Keywords

  • ELISA
  • ELISPOT
  • Pneumococcal surface protein A
  • Salmonella Typhi vaccine vector
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA. / Frey, Sharon E.; Lottenbach, Kathleen R.; Hill, Heather; Blevins, Tamara P.; Yu, Yinyi; Zhang, Ying; Brenneman, Karen E.; Kelly-Aehle, Sandra M.; McDonald, Caitlin; Jansen, Angela; Curtiss, Roy.

In: Vaccine, Vol. 31, No. 42, 01.10.2013, p. 4874-4880.

Research output: Contribution to journalArticle

Frey, SE, Lottenbach, KR, Hill, H, Blevins, TP, Yu, Y, Zhang, Y, Brenneman, KE, Kelly-Aehle, SM, McDonald, C, Jansen, A & Curtiss, R 2013, 'A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA', Vaccine, vol. 31, no. 42, pp. 4874-4880. https://doi.org/10.1016/j.vaccine.2013.07.049
Frey, Sharon E. ; Lottenbach, Kathleen R. ; Hill, Heather ; Blevins, Tamara P. ; Yu, Yinyi ; Zhang, Ying ; Brenneman, Karen E. ; Kelly-Aehle, Sandra M. ; McDonald, Caitlin ; Jansen, Angela ; Curtiss, Roy. / A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA. In: Vaccine. 2013 ; Vol. 31, No. 42. pp. 4874-4880.
@article{77e1932f47604358975348aa914cc7d3,
title = "A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA",
abstract = "Background: Live, attenuated, orally-administered Salmonella strains are excellent vectors for vaccine antigens and are attractive as vaccines based on previous use of S. Typhimurium in animals. A Phase I dose escalation trial was conducted to evaluate the safety and immunogenicity of three newly constructed recombinant attenuated Salmonella enterica serovar Typhi vaccine (RASV) vectors synthesizing Streptococcus pneumoniae surface protein A (PspA). Methods: The 3 S. Typhi strains used as vectors to deliver PspA were S. Typhi ISP1820; S. Typhi Ty2 RpoS-; and S. Typhi Ty2 RpoS+. Sixty healthy adults (median age 25.2 years) were enrolled into 4 Arms (total 15 subjects per Arm); within each Arm, subjects were randomized 1:1:1 into 3 Groups of 5. All subjects in the same Group received the same vaccine vector, and all subjects in the same Arm received the same titer of vaccine (107, 108, 109 or 1010CFU). Adverse events, safety, shedding, and IgG and IgA titers against Salmonella outer membrane proteins (OMPs), lipopolysaccharide (LPS) and PspA were evaluated. Results: In the highest dose group, no subject experienced severe reactions or serious adverse events. Most adverse events were mild; one subject had a positive blood culture. No subject shed vaccine in stool. No statistically significant differences for post vaccination ELISA or ELISPOT results between Groups were detected. However, a limited number of ≥4 fold increases from baseline for IgA anti-OMPs, IgA and IgG anti-LPS, and IgA anti-PspA occurred for a few individuals as measured by ELISA, and IgA anti-OMPs as measured by ELISPOT assay. Conclusions: All three S. Typhi vectored pneumococcal vaccines were safe and well-tolerated. Immunogenicity was limited possibly due to pre-existing high antibody titers prior to vaccination. Increases in IgA were most often observed.",
keywords = "ELISA, ELISPOT, Pneumococcal surface protein A, Salmonella Typhi vaccine vector, Streptococcus pneumoniae",
author = "Frey, {Sharon E.} and Lottenbach, {Kathleen R.} and Heather Hill and Blevins, {Tamara P.} and Yinyi Yu and Ying Zhang and Brenneman, {Karen E.} and Kelly-Aehle, {Sandra M.} and Caitlin McDonald and Angela Jansen and Roy Curtiss",
year = "2013",
month = "10",
day = "1",
doi = "10.1016/j.vaccine.2013.07.049",
language = "English (US)",
volume = "31",
pages = "4874--4880",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "42",

}

TY - JOUR

T1 - A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA

AU - Frey, Sharon E.

AU - Lottenbach, Kathleen R.

AU - Hill, Heather

AU - Blevins, Tamara P.

AU - Yu, Yinyi

AU - Zhang, Ying

AU - Brenneman, Karen E.

AU - Kelly-Aehle, Sandra M.

AU - McDonald, Caitlin

AU - Jansen, Angela

AU - Curtiss, Roy

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Background: Live, attenuated, orally-administered Salmonella strains are excellent vectors for vaccine antigens and are attractive as vaccines based on previous use of S. Typhimurium in animals. A Phase I dose escalation trial was conducted to evaluate the safety and immunogenicity of three newly constructed recombinant attenuated Salmonella enterica serovar Typhi vaccine (RASV) vectors synthesizing Streptococcus pneumoniae surface protein A (PspA). Methods: The 3 S. Typhi strains used as vectors to deliver PspA were S. Typhi ISP1820; S. Typhi Ty2 RpoS-; and S. Typhi Ty2 RpoS+. Sixty healthy adults (median age 25.2 years) were enrolled into 4 Arms (total 15 subjects per Arm); within each Arm, subjects were randomized 1:1:1 into 3 Groups of 5. All subjects in the same Group received the same vaccine vector, and all subjects in the same Arm received the same titer of vaccine (107, 108, 109 or 1010CFU). Adverse events, safety, shedding, and IgG and IgA titers against Salmonella outer membrane proteins (OMPs), lipopolysaccharide (LPS) and PspA were evaluated. Results: In the highest dose group, no subject experienced severe reactions or serious adverse events. Most adverse events were mild; one subject had a positive blood culture. No subject shed vaccine in stool. No statistically significant differences for post vaccination ELISA or ELISPOT results between Groups were detected. However, a limited number of ≥4 fold increases from baseline for IgA anti-OMPs, IgA and IgG anti-LPS, and IgA anti-PspA occurred for a few individuals as measured by ELISA, and IgA anti-OMPs as measured by ELISPOT assay. Conclusions: All three S. Typhi vectored pneumococcal vaccines were safe and well-tolerated. Immunogenicity was limited possibly due to pre-existing high antibody titers prior to vaccination. Increases in IgA were most often observed.

AB - Background: Live, attenuated, orally-administered Salmonella strains are excellent vectors for vaccine antigens and are attractive as vaccines based on previous use of S. Typhimurium in animals. A Phase I dose escalation trial was conducted to evaluate the safety and immunogenicity of three newly constructed recombinant attenuated Salmonella enterica serovar Typhi vaccine (RASV) vectors synthesizing Streptococcus pneumoniae surface protein A (PspA). Methods: The 3 S. Typhi strains used as vectors to deliver PspA were S. Typhi ISP1820; S. Typhi Ty2 RpoS-; and S. Typhi Ty2 RpoS+. Sixty healthy adults (median age 25.2 years) were enrolled into 4 Arms (total 15 subjects per Arm); within each Arm, subjects were randomized 1:1:1 into 3 Groups of 5. All subjects in the same Group received the same vaccine vector, and all subjects in the same Arm received the same titer of vaccine (107, 108, 109 or 1010CFU). Adverse events, safety, shedding, and IgG and IgA titers against Salmonella outer membrane proteins (OMPs), lipopolysaccharide (LPS) and PspA were evaluated. Results: In the highest dose group, no subject experienced severe reactions or serious adverse events. Most adverse events were mild; one subject had a positive blood culture. No subject shed vaccine in stool. No statistically significant differences for post vaccination ELISA or ELISPOT results between Groups were detected. However, a limited number of ≥4 fold increases from baseline for IgA anti-OMPs, IgA and IgG anti-LPS, and IgA anti-PspA occurred for a few individuals as measured by ELISA, and IgA anti-OMPs as measured by ELISPOT assay. Conclusions: All three S. Typhi vectored pneumococcal vaccines were safe and well-tolerated. Immunogenicity was limited possibly due to pre-existing high antibody titers prior to vaccination. Increases in IgA were most often observed.

KW - ELISA

KW - ELISPOT

KW - Pneumococcal surface protein A

KW - Salmonella Typhi vaccine vector

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=84884209157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884209157&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.07.049

DO - 10.1016/j.vaccine.2013.07.049

M3 - Article

VL - 31

SP - 4874

EP - 4880

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 42

ER -